HAO Haoxi Health Technology Ltd Annual reports only
Services-Advertising Agencies · Nasdaq · SEC CIK 1954594 · Fiscal year ends 06/30
Financial factors as of 2026-06-30 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY67.1%
TTM net income YoY-346.0%
TTM EPS YoY-111.4%
Revenue 3-yr CAGR24.8%
Net income 3-yr CAGR—
Margins
Gross margin1.1%
Operating margin-17.6%
Net margin-17.4%
FCF margin—
EBITDA margin-17.1%
Returns
ROE-54.1%
ROA-44.2%
ROIC (approx.)-93.7%
Asset turnover2.54x
Leverage & solvency
Liabilities / assets17.2%
Debt / equity0.00x
Current ratio4.53x
Interest coverage-184.27x
Cash quality & payout
Operating cash flow / net income0.27x
Accruals ratio-32.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $54.83M | $32.80M |
| Cost of revenue | $54.20M | $31.88M |
| Gross profit | $629,090 | $927,750 |
| R&D expense | $104,357 | $79,544 |
| SG&A expense | $8.61M | $2.80M |
| Operating income | -$9.66M | -$2.00M |
| Interest expense | $52,446 | $45,956 |
| Pretax income | -$9.50M | $4.15M |
| Income tax | $36,614 | $270,744 |
| Net income | -$9.54M | $3.88M |
| EBITDA | -$9.36M | -$1.71M |
| EPS (basic) | -386.40 | 4,251.81 |
| EPS (diluted) | -386.40 | 3,385.53 |
| Weighted avg. shares (diluted) | 24,680 | 936 |
| Balance sheet | ||
| Cash & equivalents | $10.93M | $8.62M |
| Receivables | $5,944 | $460,272 |
| Current assets | $16.81M | $19.60M |
| PP&E, net | $104,169 | $108,899 |
| Intangibles | — | $1.80M |
| Total assets | $21.57M | $21.60M |
| Current liabilities | $3.71M | $3.91M |
| Short-term debt | $290,710 | $300,338 |
| Long-term debt | — | $307,323 |
| Total debt | — | $607,661 |
| Total liabilities | $3.71M | $4.22M |
| Shareholders' equity | $17.86M | $17.38M |
| Net debt | — | -$8.01M |
| Cash flow statement | ||
| Operating cash flow | -$2.57M | -$3.36M |
| Investing cash flow | -$4.50M | -$3.58M |
| Financing cash flow | $9.33M | $8.90M |
| Depreciation & amortization | $308,615 | $294,611 |
| Stock-based compensation | — | $58,602 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.